Ozempic and Wegovy: Potential Anti-Cancer Benefits Revealed for Natural Killer Cells

A recent study published in the journal Obesity has uncovered a surprising potential benefit for individuals with obesity who are taking Ozempic or Wegovy to lose weight. The study indicates that these medications, which contain the active ingredient semaglutide, could aid in reducing the risk of cancer.

The research suggests that semaglutide helps restore the function of "natural killer" cells, which are crucial in fighting cancer but often malfunction in people with obesity. This article explores the findings of the study and delves into the additional benefits of taking Ozempic and Wegovy beyond weight loss.

The Connection between Semaglutide and Improved Natural Killer Cell Function

The study conducted by researchers focused on 20 individuals with obesity who had impaired natural killer cell function. All participants received weekly doses of semaglutide, a drug belonging to the class of glucagon-like peptide-1 (GLP-1) analogues initially developed for diabetes treatment but increasingly used for weight loss.

After a six-month treatment period, significant improvements in natural killer cell function were observed among the participants. Surprisingly, the level of improvement did not seem to correlate with the amount of weight loss, indicating that semaglutide and similar GLP-1 drugs may offer benefits beyond weight management.

Unveiling the Potential Additional Benefits of Ozempic and Wegovy

While previous research has produced mixed results regarding the connection between GLP-1 drugs and cancer risk, this recent study sheds new light on the matter. A 2019 meta-analysis of 37 clinical trials found that albiglutide, another GLP-1 drug no longer available, reduced the overall risk of cancer by 24 percent in people with type 2 diabetes.

However, other studies have associated GLP-1 medicines with an increased risk of thyroid cancer, pancreatic cancer, and breast cancer. The current study, although small and brief, suggests that semaglutide and other GLP-1 drugs have the potential to provide benefits beyond weight loss.

The Impact of Semaglutide on Inflammation Independent of Weight Loss

Although this study's scope was limited to individuals taking semaglutide for obesity, it holds promise for future research regarding the influence of GLP-1 drugs on cancer risk over time. Obesity has been shown to affect natural killer cells, with excess fat tissue triggering inflammation that hinders their effectiveness in fighting cancer.

The study hints that semaglutide may possess anti-inflammatory properties, as suggested by a separate study published in Pharmacological Research. By reducing inflammation associated with fat tissue, semaglutide might release the trapped natural killer cells, enabling them to regain their functionality and combat cancerous activity without requiring significant weight loss.


The recent study showcasing the potential anti-cancer benefits of Ozempic and Wegovy has opened up exciting possibilities for individuals with obesity.

Semaglutide, the active ingredient in these medications, has been found to restore natural killer cell function, which is often impaired in people with obesity. These findings suggest that beyond their primary purpose of weight loss, Ozempic and Wegovy could have additional advantages in reducing the risk of cancer.

However, further research is necessary to establish a comprehensive understanding of the long-term effects and potential benefits of GLP-1 drugs. Nevertheless, these findings offer hope in the ongoing fight against cancer, particularly in individuals with obesity.

Healthy Posters: Health and Wellness Guidance and Product Reviews